Nventa Biopharmaceuticals Corporation

Nventa Biopharmaceuticals Corporation

Company type	Public
Industry	Biopharmaceuticals
Founded	1990 in Victoria, British Columbia, Canada
Defunct	2009 (2009)
Fate	Merged with Akela Pharma, Inc.
Successor	Akela Pharma, Inc.
Headquarters	San Diego , United States
Key people	Gregory M. McKee (President and CEO), Peter Emtage, Ph.D. (VP Research and Development)
Products	HspE7 therapeutic vaccine, Poly-ICR adjuvant

Nventa Biopharmaceuticals Corporation was a biopharmaceutical firm incorporated in Canada, with its headquarters located in San Diego, California. The company specialized in creating treatments for viral infections and cancers, with a particular emphasis on conditions caused by human papillomavirus (HPV). Nventa distinguished itself as the sole enterprise utilizing heat shock protein (Hsp) technology to combat the HPV infection affecting over 20 million individuals in the United States. Originally based in Victoria, British Columbia, Canada, the company’s common shares were listed on the Toronto Stock Exchange under the ticker symbol NVN.

Development programs

The primary product candidate from Nventa was HspE7, an innovative therapeutic vaccine aimed at HPV-associated illnesses. This candidate leveraged Nventa’s proprietary CoVal fusion platform, which utilizes recombinant DNA technology to create covalent bonds between heat shock proteins and specific target antigens, thereby activating cellular immune mechanisms. Development of HspE7 included combination with the Toll-like receptor 3 (TLR3) agonist adjuvant Poly-ICLC, targeting indications such as CIN, genital warts, cervical cancer, and cancers of the head and neck region.

By December 31, 2009, funding for scientific research related to HspE7 had been discontinued.

In addition to HspE7, Nventa pursued two other therapeutic vaccine initiatives employing CoVal technology: an Hsp–HBV (hepatitis B) fusion vaccine and early-stage Hsp fusion prototypes incorporating influenza virus antigens.

In June 2008, Nventa revealed the development of a proprietary vaccine adjuvant named Poly IC – Poly Arginine (Poly-ICR), intended for use in both therapeutic and preventive vaccines. Poly-ICR functions as a TLR3 agonist that boosts cytotoxic T lymphocyte and antibody B cell responses when paired with disease-specific antigens. Preclinical studies demonstrated that Poly-ICR enhanced antigen-specific CD8+ T-cell populations and promoted tumor regression as well as growth inhibition in murine models. The company planned to utilize Poly-ICR internally while also exploring external licensing possibilities.

Clinical progress

Nventa progressed HspE7 as a monotherapy through several Phase 2 clinical trials yielding favorable results for conditions such as cervical dysplasia and recurrent respiratory papillomatosis (RRP). These studies preceded findings that vaccine adjuvants could significantly amplify therapeutic efficacy. Consequently, Nventa shifted focus toward developing HspE7 combined with the TH1-biased adjuvant Poly-ICLC. A Phase 1b trial evaluating safety and tolerability was conducted in 17 patients diagnosed with cervical intraepithelial neoplasia (CIN) and has been completed.

Senior management

Gregory M. McKee, President and Chief Executive Officer

Peter Emtage, Ph.D., Vice President, Research and Development

Merger with Akela Pharma, Inc.

On March 27, 2008, Nventa Biopharmaceuticals Corporation and Akela Pharma Inc. announced a definitive agreement to merge via a plan of arrangement governed by the Business Corporations Act. The transaction involved exchanging shares of Nventa for Akela common stock at a ratio of 0.0355 Akela shares per Nventa share, resulting in an ownership distribution approximating 70% for Akela shareholders and 30% for former Nventa shareholders.

Following the merger, the combined publicly traded entity retained the Akela Pharma name and leadership team and continued its listing on the Toronto Stock Exchange under the symbol AKL. As part of the agreement, Nventa obtained the right to appoint two directors to Akela’s board.

The merger was finalized on May 22, 2009, after receiving approvals from Nventa’s shareholders, the British Columbia Supreme Court, and the Toronto Stock Exchange.